Biopharma · FDA Approvals · Stock
CSTL Castle Biosciences
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test;…
Assets on file: TissueCypher
Catalyst calendar
Dated catalysts for CSTL, including recently decided ones.
Recent first-hand events
Every first-hand event for CSTL, newest first.
CSTLCastle BiosciencesCastle Biosciences: ACG 2026 data show TissueCypher identifies elevated BE progression risk beyond pathology
New data from three studies (two case reports, one multi-center cohort) presented at ACG 2026 demonstrate that TissueCypher provides objective molecular risk stratification (e.g., 5-year progression probabilities of 62% and 47% in high-risk cases) that changes management in 96% of patients compared to histopathology or PIB score alone, supporting earlier intervention or adjusted surveillance intervals for Barrett's Esophagus patients.
Peers by market cap
Companies in the same sector closest to CSTL in market value.
HROWHarrowMarket cap $1.1B · 2 tracked drugs · 1 upcoming catalyst
REPLReplimuneMarket cap $1.1B · 3 tracked drugs · 4 upcoming catalysts
AMPHAmphastarMarket cap $1.1B · 1 tracked drug
MNKDMannKindMarket cap $980.7M · 2 tracked drugs
CGEMCullinanMarket cap $958.2M · 3 tracked drugs · 5 upcoming catalysts
GLUEMonte RosaMarket cap $957.2M · 1 tracked drug
SVRASavaraMarket cap $955.8M · 1 tracked drug · 1 upcoming catalyst
MGTXMeiraGTxMarket cap $947.0M · 1 tracked drug